VIRxSYS to Host a Web Conference to Announce Clinical Tr...( Summary of data from...),Health

Summary of data from five 2008 conferences

GAITHERSBURG, Md., July 21 /PRNewswire/ -- VIRxSYS Corporation, a privately held company developing gene therapies for HIV and genetic diseases, will present an update on the VRX496 Phase I and Phase II clinical trials for the media and members of the advocacy community. VRX496 is an investigational gene therapy for the treatment of AIDS. The presentation will take place on Thursday, July 24, 2008 at 11 a.m. EDT. The presentation can be accessed through a secure web site, https://www.livemeeting.com/cc/vcc/join?id=w5395452&role=attend&pw=A539545 and toll-free conference line: (800) 768-6570, using the passcode 5395452.

The speakers will be:

-- Gary McGarrity, PhD, Executive Vice President for Scientific Affairs, VIRxSYS

-- Carl June, MD, Professor, Department of Pathology and Laboratory Medicine, University of Pennsylvania

"Over the last six months we have presented clinical trial update for VRX496 and preclinical development update for VRX1023 at five conferences in three countries. We wanted to take this opportunity to summarize what we have shown over the last six months as well as talk about what we have learned at the conferences regarding how VRX496 and VRX1023 might play in the treatment of HIV infection," said Riku Rautsola, PhD, President and CEO of VIRxSYS. "These conferences have not just been an opportunity to present our data, but we have also learned more about what we do and gotten feedback from leaders in the field. For example, in Paris, Dr. Fauci's presentation focused on the discovery and identification of a new immune cell receptor that binds to HIV, a cell adhesion molecule known as integrin alpha 4 beta 7 that is found to direct CD4 T cell traffic to GALT and enhance cellular interaction through forming synapses between T cells. This was interesti
'/>"/>